Good Rachel. you, thanks afternoon, Thank for joining us. everyone, and
cannabis begin followed for markets Mark fourth in industry Tilray's call this will will brief the which XXXX we will operate. our full by recap with focus in the XXXX performance, on XXXX. our I remarks on of in Then, detail. review the financial and results in I perspectives conclude the the with of ahead months quarter, state
was for US$XXX XXXX and XX% product long-term sales. forward total In These of bulk its of drive proud hemp. our businesses increased with we business highly diversified XX%, built Canada adult-use, and revenue markets, not to our of respectively, Tilray to face We XX% of XXX% position team cannabis year-over-year from core the a generated but million. firsts creation. medical, volatility, of market business executed Tilray, year across In coming global three revenue, XX% remaining the without and challenges. our year shareholder how a value to for XXXX a XXXX, I'm revenue approximately
X in available Our the medical on now world. countries cannabis continents products around XX are
around in doors over products the XX,XXX hemp countries retail Our world. XX are in available
Portugal. to Canada, in States, and only two countries, company the We facilities Canada diversified Australia, offices America. Latin the base, with Europe, cannabis GMP-certified United We're cultivation have and asset in and have a facilities
that and customers, to achieved market licensed compete time formats milestones stage of of following: promises providing first Beverage received; one our Over formerly an allow companies by very strengthening industry-leading the of to by Privateer orderly XXX Privateer for lead executive Being United Fortune with our business. to commitment Tilray Good and hemp with with us with beverage two the in and CBD-infused the the other trials global were and GMP Anheuser-Busch a Launching the the around; cannabis two product the venture clinical key in United joint far Completing position include cannabis Canadian and in thus on named years; well to Portugal research or we Tilray with of have been in functions X.X and InBev, over course our with our recipient Holdings brands course States held Manufacturing of Company our Completing attracting merger our acquisition shares within Canada; States development; of on the countries products we from furthering key release world, around XXXX, best-in-class producers the products well on talent product the Participating XX Harvest, Manitoba Delivering that Practice Fluent for product to platform the bench beverages the certifications cannabis facility; our next in
operator early the for of industry and are material remarks. operate, product. medicine in investor supply, markets To I and cannabis very and strategically industry and have secure in mainstream to cannabis development, this of still to relationships in consumer invested the build nearly shift legalization key we is and around a a now. There as global and has opportunity, decade I with been believe which consumers. the an brands in paradigm broader a on industry's I markets growth raw occurring days trajectory. Turning this in share will that the the use capitalize And and Tilray we advance patients and few research both
Our new and do we permitted when position so. markets enter global medical puts in are legally us to recreational an footprint advantageous to today
I the Over two to we followed continue cannabis legalize additional next countries believe see by to three years, medical adult-use. will
and we to chain. I investing execute portfolio win to best-in-class the company most balance vested our a haven't trusted by Tilray to assets We remains and supported our of that hemp valued well-positioned shareholder prudently globally. will have team remains to right the firmly brands, supply with focus long-term drive The world's and steadfast sheet business on multinational believe and cannabis strategy. of continue value. a build
provincial Canada, to availability. pace legal the points of the governments the from retail market, licensing. market and the slower been Primarily, past few to the taking been challenges Canadian cannabis a product We're quarters. share over illicit have increase taken of expected in and actions by of Turning has announcements due to by than and lack recent distribution market well-documented encouraged
the as availability see with Additionally, of we product evolves, high-quality industry dissipating. the issues consistent supply
XX to by point Putting months we sales market I XXXX. the year two market been into legalization the by bullish Canada in retail than and less billion than being and half are to cannabis are of over long-term one years into this illicit on estimates nearly volatile is bigger over remain the context, a opportunity extremely end of still were in expected but The in legalization and months, has the legal And billion federal and That past market. XXXX. the to C$X.X XXX% XXXX, the half X.X a grow in Canada. market the products, last C$X.X yet growth
can continued you our on for bullish to medium term long-term market to While prospects why remain volatility, the I see I industry. expect near continue
brands use our our our legalization XX products, in licensed In territories are seven in provinces allows. authorization portfolio In products to able been of have we in ship restock competitors We not. Canada, producers some to first whereas successfully and phase and day retailer Canada of product one two as today, we were brands the adult broad total, where shelves built December, have have regions a of with trusted previously two in phase the ready of mentioned. for only
As we're regulation we well-positioned Quebec, such markets. those as provinces, to serve certain in Alberta shifts see and
expanded Wowie, following: pens THC Marley InBev cartridges, Canada. Our Everie, infused cannabis milk chocolates includes with portfolio Breweries the Canaca, and currently and vape under our venture tea Chowie joint pure Labatt CBD with extracted cannabis, COX adult-use beverages CBD one Anheuser-Busch and High of varieties; through and vape cartridges; Park pure all-in sparkling Natural,
certified business. in GMP is internationally, manufacturing standards Looking particularly Europe, accordance the our building In December, Tilray Portugal GMP medical medical second European dried Union cannabis our oils cannabis international Portugal, markets certification for including from in formulate, in in European to made Germany Portugal products, our Tilray regulations. Cantanhede, great with GMP flower with its allows Portugal. manufacture strides second and us and to and facility and for legal which finished late have certification we received export This other
received XXXX. expect GMP our Since X.X-day certification we to Portugal Switzerland. exported first to in to GMP Germany to active receive May, export, Germany of extraction, oil Israel final half inspection medical successfully first we as in certification Portugal, and certified had have an week, which certifications, cannabis products. cannabis our and and receiving from we for manufacture for these GMP from in Portugal third substance we and a dried GMP And medical Last last for the
sites our distribution expect Union processing, international our indoor, labs, We Portugal, hub and sites, European for research increase products. to will for which as with exports and greenhouse packaging be in from well cultivation campus operations our outdoor as medical
Our cultivation processing greater capacity. our capacity is than
finish and raw So, to with we have materials and cultivation prepare scale ample finished grow, capacity. in third our parties runway from to own goods addition
Portugal, footprint feet for Our and facility. feet a XXX,XXX growth square and million million is outdoor space, square X.X of X.X greenhouse in processing square including feet
the partnered kind products. international the in XXX%. research among research fourth industry to foster greenhouse XXXX, lacking markets. In to Tilray also first processing develop we clinical its medical by to acceptance capacity believe medical University and a data we in expect within and our Portugal quarter, governments Coimbra with of help Portugal of the increase is and will mainstream strategic community partnership The cannabis-derived In
CBD remain legally building U.S. we’re of core is over with so. the U.S. retails Harvest Manitoba products focused United a where consumer-centric asset States in hemp do States, we to XX,XXX In on -- today. brands permitted portfolio a doors
and are FDA's CBD guidance make We before in this await around clarity further investments monitoring closely further we the market.
team of would and or we base. like cancer quarter, changes XX% the to medical peripheral undergoing new Columbia broader our our comment During on to neuropathy, employee women for into the also the medical TIPN University, conducted of we cannabis by cannabis efficacy United fourth quarter, treatment as for Canada imported affects treatment. evaluating executive I clinical from States fourth Since trial taxane-induced a closed breast a which
Levin as incoming executive as Kruteck January, new Financial team In who with Pharmaca. Coors Michael two our Chief Jon Officer, Operating formerly was and we formerly leadership strengthened was with hires, Revlon; with who Molson Officer, Chief
We're current expertise will this and involved announced January, be strategic Michael's closely As will within industry. Tilray continue ever-changing transitioning to be to development Mark's Mark Castaneda, navigate business in having happy CFO, a role in as our transition. we
Katy on brought former Mills General and Additionally, Harvest. December, Dickson President last of executive, Mattel we Manitoba as
businesses the XXXX focus Each make restructure While capital. investor organization goals. meet focus our competitive been and duplication to return reviewed a to on led operating invested increase rapid our of hires, us also we key broader the have our profitability order efficiencies, with to with costs to align and in continue reduce our shift to better on in landscape
XX% we of As a XXXX, global approximately result, in headcount. eliminated February our
in and leading companies Tilray has these when our easy, needed. been because of being decisions successful pivot the to ability never While one are of react cannabis
obtaining markets out certification aggressively that the the Continuing of serve; medical strategic and way, into our market optimizing growth; of market cost X.X the restock strategic XXXX, Portugal products medical We current there; Completing the efficiencies; phase only regulations or growing finally, offerings medical, Tilray partnerships make in where share, disciplined, our becoming to our entering balance positive the products enter final XXXX. investments anticipate across product driving assets into countries we and accelerate anticipate us hemp GMP product evaluate currently our some of in our to enable allow; facility QX following: will of partnerships adult-use footprint. we build EBITDA cannabis international For Canada further and and we in Canadian where and expanding and our new global Exporting opportunities to our warranted. to Along
call With I the turn to like would Mark. that, to over